GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer.

Although a similar interaction between FOXA1 and tamoxifen did not reach statistical significance ( p = 0.22), the benefit from the treatment was more evident in the group with higher levels as compared with the group with low levels (HR = 0.41 (0.26–0.63), p = 0.000075) and (HR = 0.71 (0.32–1.58), p = 0.40), respectively, (Fig. 6c, d ).

also in 111,027 other papers